AU2014225155B2 - Pyridopyrimidine or pyrimidopyrimidine compound, preparation method, pharmaceutical composition and use thereof - Google Patents

Pyridopyrimidine or pyrimidopyrimidine compound, preparation method, pharmaceutical composition and use thereof Download PDF

Info

Publication number
AU2014225155B2
AU2014225155B2 AU2014225155A AU2014225155A AU2014225155B2 AU 2014225155 B2 AU2014225155 B2 AU 2014225155B2 AU 2014225155 A AU2014225155 A AU 2014225155A AU 2014225155 A AU2014225155 A AU 2014225155A AU 2014225155 B2 AU2014225155 B2 AU 2014225155B2
Authority
AU
Australia
Prior art keywords
oxa
azabicyclo
compound
title compound
octanyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014225155A
Other languages
English (en)
Other versions
AU2014225155A1 (en
Inventor
Yiyi CHEN
Lanping Ma
Lanfang MENG
Tao Meng
Jingkang Shen
Xin Wang
Ke Yu
Arie Zask
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Materia Medica
Shandong Luoxin Pharmaceutical Group Co Ltd
Fudan University
Original Assignee
Shanghai Institute of Materia Medica
Shandong Luoxin Pharmaceutical Group Co Ltd
Shandong Luoxin Pharmaceutical Co Ltd
Fudan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica, Shandong Luoxin Pharmaceutical Group Co Ltd, Shandong Luoxin Pharmaceutical Co Ltd, Fudan University filed Critical Shanghai Institute of Materia Medica
Publication of AU2014225155A1 publication Critical patent/AU2014225155A1/en
Assigned to SHANDONG LUOXIN PARMACEUTICAL GROUP STOCK CO., LTD. reassignment SHANDONG LUOXIN PARMACEUTICAL GROUP STOCK CO., LTD. Request for Assignment Assignors: FUDAN UNIVERSITY, SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
Application granted granted Critical
Publication of AU2014225155B2 publication Critical patent/AU2014225155B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2014225155A 2013-03-04 2014-02-28 Pyridopyrimidine or pyrimidopyrimidine compound, preparation method, pharmaceutical composition and use thereof Ceased AU2014225155B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201310068888.8A CN103588792B (zh) 2013-03-04 2013-03-04 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途
CN201310068888.8 2013-03-04
PCT/CN2014/072678 WO2014135028A1 (zh) 2013-03-04 2014-02-28 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途

Publications (2)

Publication Number Publication Date
AU2014225155A1 AU2014225155A1 (en) 2015-10-15
AU2014225155B2 true AU2014225155B2 (en) 2017-11-23

Family

ID=50079144

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014225155A Ceased AU2014225155B2 (en) 2013-03-04 2014-02-28 Pyridopyrimidine or pyrimidopyrimidine compound, preparation method, pharmaceutical composition and use thereof

Country Status (11)

Country Link
US (1) US9796732B2 (enExample)
EP (1) EP2966079B1 (enExample)
JP (1) JP2016510042A (enExample)
CN (1) CN103588792B (enExample)
AU (1) AU2014225155B2 (enExample)
CA (1) CA2903072C (enExample)
DE (1) DE14760712T1 (enExample)
DK (1) DK2966079T3 (enExample)
ES (1) ES2572105T3 (enExample)
RU (1) RU2662713C2 (enExample)
WO (1) WO2014135028A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103588792B (zh) * 2013-03-04 2016-03-23 中国科学院上海药物研究所 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途
CN106008559B (zh) * 2015-03-25 2020-10-16 中国科学院上海药物研究所 取代吡啶并嘧啶类化合物的合成工艺
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
WO2019091400A1 (zh) * 2017-11-07 2019-05-16 中国科学院上海药物研究所 吡啶并嘧啶类化合物的盐型和晶型及其制备方法
CN109867667B (zh) * 2017-12-05 2021-06-11 中国药科大学 含有吡啶并嘧啶结构的parp和pi3k双靶点抑制剂
CN113825760B (zh) * 2019-05-06 2022-08-19 南京明德新药研发有限公司 一种mTORC1/2双激酶活性抑制剂的盐型、晶型及其制备方法
WO2021247859A1 (en) * 2020-06-03 2021-12-09 Yumanity Therapeutics, Inc. Pyridopyrimidines and methods of their use
WO2022061251A1 (en) * 2020-09-18 2022-03-24 Plexxikon Inc. Compounds and methods for kras modulation and indications therefor
CN115260158A (zh) * 2021-04-30 2022-11-01 上海医药集团股份有限公司 一种靶向蛋白调节剂的化合物及其应用
WO2023018812A1 (en) * 2021-08-10 2023-02-16 Amgen Inc. Heterocyclic compounds and methods of use
JP2024532735A (ja) * 2021-08-10 2024-09-10 アムジエン・インコーポレーテツド 複素環式化合物及び使用方法
US20240417412A1 (en) * 2021-08-10 2024-12-19 Amgen Inc. Heterocyclic compounds and methods of use
JP2025519743A (ja) * 2022-06-15 2025-06-26 ミラティ セラピューティクス， インコーポレイテッド 汎ＫＲａｓ阻害剤のプロドラッグ
WO2024057013A1 (en) * 2022-09-12 2024-03-21 Exscientia Ai Limited Nlrp3 modulators
CN117586255A (zh) * 2023-09-25 2024-02-23 上海图芃生物科技有限公司 一种口服atp竞争性激酶抑制剂及其合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102887895A (zh) * 2011-07-22 2013-01-23 山东轩竹医药科技有限公司 吡啶并嘧啶类mTOR抑制剂
WO2013016999A1 (zh) * 2011-08-04 2013-02-07 江苏豪森药业股份有限公司 杂芳基并嘧啶类衍生物、其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007010401A (es) * 2005-02-25 2008-02-19 Kudos Pharm Ltd Derivados de 2,4-diamino-piridopirimidina y su uso como inhbidores de mtor.
UA96745C2 (en) * 2005-11-22 2011-12-12 Кудос Фармасьютикалз Лимитед PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
AU2007282535B9 (en) * 2006-08-08 2013-06-20 Chugai Seiyaku Kabushiki Kaisha Pyrimidine derivative as PI3K inhibitor and use thereof
CN101558067B (zh) * 2006-08-23 2014-05-28 库多斯药物有限公司 作为mtor抑制剂的2-甲基吗啉吡啶并、吡唑并和嘧啶并-嘧啶衍生物
US20080233127A1 (en) * 2007-03-21 2008-09-25 Wyeth Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
WO2010120987A1 (en) * 2009-04-17 2010-10-21 Wyeth Llc Ring fused, ureidoaryl- and carbamoylaryl-bridged morpholino-pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
CN103588792B (zh) * 2013-03-04 2016-03-23 中国科学院上海药物研究所 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102887895A (zh) * 2011-07-22 2013-01-23 山东轩竹医药科技有限公司 吡啶并嘧啶类mTOR抑制剂
WO2013016999A1 (zh) * 2011-08-04 2013-02-07 江苏豪森药业股份有限公司 杂芳基并嘧啶类衍生物、其制备方法和用途

Also Published As

Publication number Publication date
US20150368274A1 (en) 2015-12-24
DK2966079T1 (da) 2016-05-17
EP2966079A1 (en) 2016-01-13
EP2966079B1 (en) 2021-11-24
CA2903072C (en) 2019-05-07
CN103588792B (zh) 2016-03-23
RU2662713C2 (ru) 2018-07-27
HK1217197A1 (en) 2016-12-30
RU2015140387A (ru) 2017-03-30
DK2966079T3 (da) 2022-02-14
CA2903072A1 (en) 2014-09-12
AU2014225155A1 (en) 2015-10-15
ES2572105T3 (es) 2022-04-13
ES2572105T1 (es) 2016-05-30
WO2014135028A1 (zh) 2014-09-12
DE14760712T1 (de) 2017-12-14
US9796732B2 (en) 2017-10-24
CN103588792A (zh) 2014-02-19
JP2016510042A (ja) 2016-04-04
EP2966079A4 (en) 2016-11-09

Similar Documents

Publication Publication Date Title
EP2966079B1 (en) Pyridopyrimidine or pyrimidopyrimidine compound, preparation method, pharmaceutical composition and use thereof
US9890168B2 (en) 2,4-disubstituted 7H-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof
CN112778275A (zh) 金刚烷基prmt5抑制剂及其应用
US11130762B2 (en) Azaaryl derivative, preparation method therefor, and application thereof for use in pharmacy
CN101932584A (zh) 作为pi3k阻滞剂的吡咯并嘧啶衍生物及其用途
JP2021050231A (ja) 結晶性ｆｇｆｒ４阻害剤化合物およびその使用
WO2019158025A1 (zh) 一种三氮唑并嘧啶衍生化合物、包含其的药物组合物及其用途
BR112016022342B1 (pt) Derivados de (5,6-di-hidro)pirimido[4,5-e] indolizinas, suas composições farmacêuticas, e seus usos
WO2005085252A1 (en) Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases
CN115677730B (zh) 8-氧-3-氮杂二环[3.2.1]辛烷类化合物或其盐及其制备方法和用途
JP2018135268A (ja) 新規ヘテロアリールアミノ−３−ピラゾール誘導体およびその薬理学上許容される塩
WO2023020209A1 (zh) 含2-芳杂环取代的脲类化合物、其制备方法和用途
CN104557913B (zh) 吡啶并嘧啶类化合物，其制备方法和用途
Liu et al. Design and synthesis of alkyl substituted pyridino [2, 3-D] pyrimidine compounds as PI3Kα/mTOR dual inhibitors with improved pharmacokinetic properties and potent in vivo antitumor activity
JP7335972B2 (ja) ピペラジンアミド誘導体、その製造方法及び医薬におけるその用途
CN115894500B (zh) 一种作为btk激酶抑制剂的化合物及其制备方法与用途
HK1217197B (en) Pyridopyrimidine or pyrimidopyrimidine compound, preparation method, pharmaceutical composition and use thereof
CN116854709A (zh) Bruton′s酪氨酸激酶可逆抑制剂及其应用
EA050883B1 (ru) 8-окса-3-азабицикло[3.2.1]октановые соединения или их соли, способ их получения и применение
HK40064179A (en) Piperazine amide derivative, preparation method therefor, and use thereof in medicine
HK1146937A (en) Pyrrolopyrimidin derivative for use as pi3k inhibitor, and use thereof

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SHANDONG LUOXIN PARMACEUTICAL GROUP STOCK CO., LTD

Free format text: FORMER APPLICANT(S): SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES; FUDAN UNIVERSITY

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE APPLICANTS TO READ SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.; SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES AND FUDAN UNIVERSITY

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS WAS NOTIFIED IN THE SUPPLEMENT TO THE OFFICIAL JOURNAL DATED 22 MAR 2018

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired